Alp Bio – Immunogenicity intelligence, grounded in human biology.

The Challenge

B-cell immunogenicity is the silent killer of antibody programs.

— Problem

ADA formation derails late-stage biologics

ADA formation affects up to 30% of biologic programs, yet no existing tool captures the full picture. In-silico models ignore B-cell epitopes. In vitro assays are static. Animal models don’t reflect human biology. The tools are fragmented. The risk is not.

— Solution

Catch ADA at lead optimization, not Phase II

ALP Bio reduces immunogenicity risk by integrating human tonsil–derived ex vivo immune data with advanced protein AI models.
Using population-scale immune response patterns, we assess and engineer antibody sequences to lower ADA probability ahead of clinical development.

Platform →

Our Platform

Three layers.
One integrated solution.

The missing piece is the data. We built our platform on tonsil organoids, the only ex vivo model that replicates human B and T cell interactions at scale.

01 — Predict

In silico ADA screening

Protein language and geometric deep learning models assess your VH/VL sequences for epitope and overall ADA risk. This fast screening enables large-scale antibody panel evaluation and helps identify the lowest-risk candidates early.

02 — Validate

Tonsil organoid ADA assay

Therapeutic candidates are tested in our proprietary tonsil organoid system, a human-derived ex vivo assay that captures the key immune interactions behind ADA formation. This reveals candidate-specific immunogenic risk across patient populations.

03 — Re-engineer

Generative biobetter design

Flagged epitopes are redesigned with our generative AI to preserve function while reducing immunogenic risk. This lab-in-the-loop platform iterates between design, in vitro testing, and ex vivo validation until liabilities are resolved.